The Peter Attia Drive - May 08, 2023


#253 ‒ Hormone replacement therapy and the Women's Health Initiative: re-examining the results, the link to breast cancer, and weighing the risk vs reward of HRT | JoAnn Manson, M.D.

Topics
Hosted by
Guests
Mentioned
#252 ‒ Latest insights on Alzheimer's disease, cancer, exercise, nutrition, and fasting | Rhonda Patrick, Ph.D. #254 - AMA #47: Cold therapy: pros, cons, and its impact on longevity

Episode Stats


Length

1 hour and 20 minutes

Words per minute

147.96

Word count

11,929

Sentence count

591

Harmful content

Misogyny

49

sentences flagged

Hate speech

20

sentences flagged


Summary

Summaries generated with gmurro/bart-large-finetuned-filtered-spotify-podcast-summ .

Dr. Joanne Manson is a Professor of Medicine and the Michael and Lee Bell Professor of Women's Health at Harvard Medical School. She is also a physician, epidemiologist, and endocrinologist, and the principal investigator or co-PI of several research studies, including the Women s Health Initiative. She has published more than 1,200 peer-reviewed articles in the medical literature, and is the author or editor of several books and textbooks. She serves as the editor-in-chief of Contemporary Clinical Trials and the past President of the North American Menopause Society. She is one of the most highly cited researchers in the history of published research and is featured in the National Library of Medicine's exhibition, History of American Women Physicians.

Transcript

Transcript generated with Whisper (turbo).
Misogyny classifications generated with MilaNLProc/bert-base-uncased-ear-misogyny .
Hate speech classifications generated with facebook/roberta-hate-speech-dynabench-r4-target .
Topics generated with Qwen2.5-3B-Instruct.
Hosts, guests, and mentioned names generated with spaCy (en_core_web_sm), reconciled against Wikidata.
00:00:00 Hey everyone, welcome to the drive podcast. I'm your host, Peter Atiyah. This podcast,
00:00:15 my website and my weekly newsletter all focus on the goal of translating the science of longevity
00:00:19 into something accessible for everyone. Our goal is to provide the best content in health and
00:00:24 wellness full stop. And we've assembled a great team of analysts to make this happen.
00:00:28 If you enjoy this podcast, we've created a membership program that brings you far more
00:00:33 in-depth content. If you want to take your knowledge of the space to the next level at
00:00:37 the end of this episode, I'll explain what those benefits are. Or if you want to learn more now,
00:00:41 head over to peteratiyahmd.com forward slash subscribe. Now, without further delay,
00:00:47 here's today's episode. My guest this week is Dr. Joanne Manson. Joanne is a professor of medicine 0.97
00:00:55 and the Michael and Lee Bell professor of women's health at Harvard Medical School,
00:01:01 professor in the department of epidemiology, along with chief of the division of prevention medicine
00:01:06 at Brigham and Women's Hospital. She is also a physician, epidemiologist, endocrinologist,
00:01:12 and the principal investigator or co-PI of several research studies, including the Women's Health
00:01:17 Initiative, which we of course discuss here in length, along with other studies such as the
00:01:21 cardiovascular components of the nurse's health study, the vitamin D and omega-3 trials known as
00:01:27 VITAL. Her primary research interests include randomized clinical prevention trials of nutrition
00:01:33 and lifestyle factors related to heart disease, diabetes, cancer, and the role of endogenous and
00:01:38 exogenous estrogens as determinants of chronic disease in women. Joanne has received numerous honors,
00:01:44 including the American Heart Association's Population Research Prize, the American Heart Association's
00:01:50 Distinguished Science Award, the Research Achievement Award, election to the Institute of Medical of the
00:01:56 National Academies and the National Academy of Medicine, membership in the Association of American
00:02:01 Physicians, fellowship in the AAAS, and so many other awards that I could spend the rest of the
00:02:07 introduction of this podcast going over them. She has published more than 1,200 peer-reviewed articles
00:02:13 in the medical literature and is the author or editor of several books and textbooks. She serves as the
00:02:18 editor-in-chief of Contemporary Clinical Trials and is the past president of the North American
00:02:23 Menopause Society. She is one of the most highly cited researchers in the history of published research
00:02:29 and one of the physicians who is featured in the National Library of Medicine's exhibition,
00:02:36 History of American Women Physicians. In this episode with Joanne, we spend the entire conversation
00:02:41 focusing on one of her main projects, the study that she was involved in called the Women's Health
00:02:48 Initiative, of which she was one of the principal investigators. In this discussion, we speak
00:02:53 about the reasons for the study, the questions being examined, the study design, inclusion-exclusion
00:02:58 criteria. We then go into the nuances of the study, including why it was prematurely stopped and how it was
00:03:06 interpreted. Of course, the most important part of this discussion is what the implications are for
00:03:13 someone today listening to this. Hormone replacement therapy is potentially one of the most controversial
00:03:19 bits of medicine today. And I would argue, and I make this point to Joanne, that the misinterpretation
00:03:27 of the Women's Health Initiative some 20 years ago may be one of the greatest missteps of medicine and,
00:03:34 by extension, the medical press in the past several decades. I make no bones about my bias here in this
00:03:41 podcast, which is that I think the fears of hormone replacement therapy are completely overblown and are
00:03:49 generally being propagated by people who are not familiar with the literature, which is why I wanted
00:03:53 to sit down with Joanne today. I could think of no better person to sit down with and go through the
00:03:59 details of this study than the person who is more familiar with them than anyone else. So, without further
00:04:05 delay, please enjoy my conversation with Dr. Joanne Manson. Joanne, it is great to finally be sitting
00:04:17 down with you. This is a topic that is arguably as important as any topic that we'll cover in this
00:04:22 podcast, and there's probably no better person to speak with about HRT than you. So, maybe just by way
00:04:30 of background, well, maybe I'll introduce you with one interesting statistic. Do you know how to
00:04:36 actually calculate the H-index? Yes. Okay. So, tell folks what the H-index is, how it's calculated.
00:04:44 I'll embarrass you by telling people how high you rank on that. Okay. This is very embarrassing,
00:04:49 Peter, but let me start by saying it's great to have a chance to talk with you, and I'm so glad that
00:04:55 you're interested in this subject and providing more information to your audience on this subject.
00:05:01 The H-index is calculated from the number of publications you have that are highly cited.
00:05:11 If, for example, you have an H-index of 100, that would mean that you have at least, we have 100
00:05:18 publications that have 100 or more citations each. An H-index of 200 would be 200 publications that each
00:05:30 have at least 200 citations are referenced in other publications. You know, we throw those numbers out
00:05:38 like 100 and 200. Those are epic H-indexes. I mean, a person with an H-index of 100 has done 10 people's,
00:05:47 you know, lifetimes work in their lifetime. Your H-index, Joanne, last I checked, is 305. Is that 0.72
00:05:54 correct? It may have crept up even higher. Yeah. Well, I would say that you are generally in the
00:06:04 top three H-index rankings in the history of biomedical science. And I know this because I've
00:06:12 checked this. I've never interviewed anybody with a higher H-index than you, and I've certainly
00:06:16 interviewed a lot of people with a very high H-index. So with that as a little bit of background,
00:06:21 let's go into a slightly more... It means I have wonderful colleagues and collaborations going on
00:06:26 throughout the world. Yeah, it certainly does. But let's talk more specifically about this
00:06:30 discussion. So there is a study that many people have heard me talk about. It's called the Women's
00:06:35 Health Initiative. It's a study that you were one of the principal investigators on. And it's also a
00:06:39 study that has produced results that I think we would look back today, 20 years later, and say
00:06:45 maybe weren't interpreted in the best way. And the implications of that are obviously significant
00:06:50 from a public health perspective. But let's go back in time to the beginning of the planning of
00:06:56 this study, which I assume would have been in the early 90s, is about when you and your peers decided
00:07:01 we needed a randomized experiment to test what was being found in the Nurses' Health Study and other
00:07:07 epidemiologic studies. Exactly. It was the very early 1990s.
00:07:13 Talk a little bit about what was observed through the observational studies, the epidemiologic studies,
00:07:18 and how that shaped the design of the WHI. Yes. So back in the 1980s and 1990s, there were several
00:07:27 observational studies. These are not randomized clinical trials, but large observational studies looking at
00:07:35 women who chose to be on hormone therapy or whom doctors were prescribing hormone therapy for.
00:07:40 And they did tend to have lower rates of heart disease in those studies compared to women not 0.79
00:07:48 using hormone therapy. They also seemed to have more favorable outcomes, such as less cognitive decline,
00:07:56 lower all-cause mortality rates. They were generally doing better. But we often say that observational
00:08:04 studies of this nature cannot prove a cause and effect relationship, but they can generate hypotheses
00:08:13 to be tested in randomized clinical trials. But before the randomized clinical trials were even launched
00:08:21 in the early 1990s, there was already an increasing practice in clinical medicine to prescribe hormone
00:08:30 therapy for the express purpose of trying to prevent heart disease, cognitive decline, and other chronic
00:08:40 diseases. So this was a trend that was occurring not only in recently menopausal women, not only when
00:08:49 women had hot flashes and night sweats and were in early menopause, but many clinicians were starting to
00:08:57 prescribe these hormones for women who were well over a decade, 10, 20, 30 years after the onset of menopause.
00:09:06 So it's very important to understand whether this practice of prescribing menopausal estrogen therapy or
00:09:16 estrogen plus progestin therapy was advisable when used for prevention of chronic diseases. This was a very
00:09:27 very different question compared to question compared to asking, does hormone therapy reduce hot flashes,
00:09:34 night sweats, and should women in their 40s, early 50s, who are just starting to go through menopause and have these
00:09:42 symptoms, should they take hormone therapy to treat those symptoms? It was accepted that hormone therapy is
00:09:51 effective for treating hot flashes and night sweats. It's actually FDA approved for that purpose. It has an
00:10:01 indication for treatment to reduce hot flashes and night sweats. But the question of its use for prevention of
00:10:09 heart disease, stroke, cognitive decline, other chronic diseases had never been tested in a randomized
00:10:17 clinical trial. And that was the goal of the Women's Health Initiative. Despite the fact that the
00:10:22 epidemiology suggested benefits in all of those arenas, people who listen to this podcast are no
00:10:27 strangers to the different types of biases that can creep in. And perhaps there's no greater bias that
00:10:33 creeps into something like this than the healthy user bias. It could easily be the case that the women who had 0.98
00:10:38 access to physicians or who had access to the type of physicians who maybe felt more knowledgeable or
00:10:45 provided better care. And part of that could have been the provision of hormones. It could be that
00:10:50 they were coming down with fewer cases of chronic diseases, not because of the hormone replacement
00:10:56 therapy, but because of other factors that were a part of a healthy lifestyle of which hormones might
00:11:01 have been a part of it. So there's no doubt that an RCT is going to be essential to carry out the
00:11:06 elucidation of causality here. Let's also talk a little bit about the formulations. I guess if we go back into
00:11:12 probably, gosh, the 1960s when the idea first came along to physicians to replace estrogen in a
00:11:20 menopausal woman, I think they were just probably using estrogen alone, correct? And they didn't 1.00
00:11:25 understand the role of progesterone as opposition to that to prevent endometrial hyperplasia. But where
00:11:31 were we in the early 90s? Clearly that had been figured out. What were the formulations that were most
00:11:37 common? Well, that's a very important question, Peter. And the most common formulations were
00:11:42 conjugated estrogen with and without medroxyprogesterone acetate. And so women who had a
00:11:49 hysterectomy could use estrogen alone, but women with an intact uterus needed to take a, what we call a 1.00
00:11:57 progestogen, which counteracts the effect of estrogen on increasing the thickness of the uterine lining,
00:12:06 the endometrium. And so if women who have an intact uterus take estrogen alone, they have a very high
00:12:13 risk of developing endometrial cancer. And early on, they will just have proliferation of the lining of
00:12:20 the uterus and increased vaginal bleeding related to taking estrogen without the progestogen. So those
00:12:28 were the two formulations that were very commonly used. And also importantly, those were the two
00:12:34 formulations that had been extensively studied in the observational studies where the results had
00:12:42 looked very promising for a lower risk of heart disease and cognitive decline, all-cause mortality.
00:12:49 So it was felt to be important to test the formulations that had contributed so much to the observational
00:12:57 study findings. As you say, the women who were taking hormone therapy in the observational studies
00:13:04 tended to be a higher socioeconomic status, more highly educated, and more health conscious. And these
00:13:12 were all potential confounding factors that may have contributed to their lower risk of chronic diseases.
00:13:21 However, it's also important to note that in observational studies, the women who were being
00:13:27 prescribed hormone therapy were still largely women in early menopause. They were at least being
00:13:34 started in early menopause, even if they continued into mid and later menopause. So that's another
00:13:41 important, perhaps biological difference between the women in the observational studies and women in 0.95
00:13:47 randomized trials, where in the Women's Health Initiative, the average age was 63 or more than a decade
00:13:55 past onset of menopause when the hormone therapy was being started.
00:13:59 I know you're not a gynecologist, so you may not know the answer to this, but do we know if the age
00:14:06 of menopause is moving over time? I mean, we certainly know that girls are getting their periods 0.65
00:14:12 earlier and earlier, even over just two decades. Do we know if menopause is also a moving target?
00:14:18 I don't know that that's been studied really rigorously and systematically. The average age of
00:14:25 menopause is 51. I believe that stayed relatively constant for quite a while. Although, as you say,
00:14:33 the age of puberty and menarche, start of menstrual periods, has become younger over time. So there are
00:14:42 those changes, but I don't know that there have been really clear differences in the age at menopause.
00:14:48 Do you have a sense of why the conjugated equine estrogen and the MPA, a synthetic progesterone,
00:14:56 were the dominant forms of these hormones used in the 80s and in the 90s, which of course then
00:15:02 became the precursor for the epidemiology? For example, do we know why there was not just a
00:15:07 bioidentical estradiol and progesterone, which of course is, we'll talk about those things later in
00:15:12 our discussion because of course those are the most dominant forms used today. But do you have a sense of
00:15:16 just historically why that was not the case even at the outset?
00:15:20 There are some theories about that, Peter. You know, one theory is that a pharmaceutical company
00:15:26 developed the conjugated estrogens. As you know, they were originally, and even many of the forms
00:15:33 today, derived from the pregnant mare's urine. And this pharmaceutical company really became the
00:15:40 dominant force in terms of hormone therapy. And the synthesis of estradiol, you know, from plants,
00:15:49 and it's a more complicated process that really did not get going on a very large scale until more
00:15:56 recent decades. But for quite a long time, many, many decades, more than 50 years, there was, you know,
00:16:03 the conjugated estrogen available. So the investigators of which you're, how many of you were actually sort
00:16:11 of lead PIs? Were there three of you? In the overall Women's Health Initiative, there were initially 16
00:16:17 clinical centers and then expanded to 40 clinical centers for most of the duration of the WHI. So
00:16:25 there were actually 40 principal investigators throughout the country. Let's go over sort of
00:16:30 study design and participant criteria, inclusion and exclusion criteria. So you've already alluded
00:16:34 to several of these. And this is a very important distinction. And it's something I think you and I
00:16:38 even discussed many, many years ago, not on a podcast, but just over the phone one day, which was
00:16:43 women who were having vasomotor symptoms were excluded, correct? No. We're not excluded. This actually is a
00:16:50 common misconception that women could not have hot flashes to participate in the WHI. Women who had 1.00
00:16:58 very severe hot flashes self-selected out of the study because they wanted, generally, they wanted
00:17:06 to be on hormone therapy. At that time, the assumption was that hormone therapy would have
00:17:12 very favorable effects. And they were already taking hormone therapy very often for their severe hot
00:17:20 flashes. So they did not want to be in the study. But we didn't exclude any woman on the basis of the
00:17:26 severity of her symptoms or presence or absence of hot flashes, night sweats. In fact, the majority 0.52
00:17:32 of the women in the study, especially those in the earlier younger menopausal ages, did have at least
00:17:41 mild or moderate hot flashes.
00:17:44 I see. I misunderstood you. I thought the thinking was by minimizing the number of women who had
00:17:50 vasomotor symptoms, you would have less dropouts in the placebo group because, of course, women who were 1.00
00:17:56 getting a placebo would presumably not be relieved of those symptoms, which are obviously the most
00:18:01 responsive to the HRT. You said the average age was 63.
00:18:05 Is that correct?
00:18:06 What were the exclusion criteria?
00:18:09 So women could not have a prior history of breast cancer, endometrial cancer, or any other
00:18:18 estrogen-sensitive cancers. And overall, if they had cancer, it had to be, could not be estrogen-sensitive
00:18:25 cancer. And it had to be more than 10 years previously. Women could not have a recent heart 1.00
00:18:31 attack or stroke or any of those major clinical cardiovascular events, although a very small
00:18:38 percentage of the women did have a more remote history of heart attack, stroke, bypass surgery,
00:18:46 that type of clinical history. For the most part, the women were healthy in terms of past history of
00:18:54 cardiovascular disease, cancer, other conditions. They were certainly allowed to have diabetes,
00:18:59 hypertension, high cholesterol, and many of the more common health conditions that women will have
00:19:07 and men will have in midlife. 0.99
00:19:10 Smoking, not an issue.
00:19:11 They were not excluded for smoking, though we had a small percentage, less than 10%.
00:19:16 Osteopenia, osteoporosis was not an exclusion?
00:19:19 It was not an exclusion. They were not selected on being required to have osteoporosis or osteopenia,
00:19:27 but it was a broad range of bone health, similar to what you would expect in the usual population
00:19:33 for women age 50 to 79.
00:19:37 And what about family history for breast cancer or uterine cancer?
00:19:42 Women were allowed to participate. It was really up to them whether they thought,
00:19:49 that their family history was so strong that they did not want to take any chance of being randomized
00:19:54 to active hormone therapy. Many women did self-select out of the study for that reason,
00:20:01 but they were not excluded by these study investigators on the basis of their family history.
00:20:08 And was there a limit as to how long they could be out of menopause before enrollment?
00:20:13 No, it was on...
00:20:14 Sorry, into menopause, yeah.
00:20:15 The criteria were based on age. So the women were 50 to 79 with a mean age of 63. Some of them had gone 1.00
00:20:25 through menopause in their early to mid 40s. Some of them had even had hysterectomy with ovaries removed
00:20:34 in their 40s or much earlier in life. So there was no exclusion on the basis of, for example,
00:20:43 being more than 20 or 30 years past menopause. It was on the basis of age 50 to 79.
00:20:50 Wow. Amazing diversity of age there, right? I mean, you think about it's basically three
00:20:55 decades worth. What about prior hormone use? What fraction of the women had previously been on 0.97
00:21:02 the exact same drugs that they were going to be potentially randomized to? And was there a required
00:21:07 period of washout? Okay, very good question. About 25% of the women in the estrogen plus progestin trial
00:21:15 had prior use of hormone therapy. And close to 50% of the women with hysterectomy and in the estrogen
00:21:25 alone trial had some prior use of estrogen therapy. So women were not excluded for having a past history
00:21:35 of using hormone therapy. But especially in the estrogen plus progestin trial, the large majority
00:21:42 did not have prior use. It was only about 25% who had prior use. And overall, just looking more
00:21:50 specifically at the percentage of women in the trial who had hot flashes, night sweats at the time 0.70
00:21:58 of enrollment, it was overall about 45%, 45 to 50% who had some symptoms, mostly mild or moderate hot
00:22:11 flashes or night sweats. And a little over 50% did not have any hot flashes or night sweats at the start
00:22:19 of the trial. How many women are enrolled in this trial? About just under 30,000, am I remembering that
00:22:24 correctly? Yes. So 27,000, a little over 27,000 in the two trials combined. In the estrogen plus
00:22:31 progestin trial, close to 17,000. In the estrogen alone trial, close to 10,000. And again, we've stated
00:22:40 this, but I think it's very important that people again understand why there are two trials. If a woman 1.00
00:22:45 has a uterus, she must be receiving progestin along with the estrogen. So that's the E plus P trial that 0.90
00:22:53 we'll talk about. If a woman has had a hysterectomy, then estrogen alone is sufficient. There's no risk
00:22:59 of endometrial hyperplasia because there is no endometrium. And there's an E alone trial. Each
00:23:05 group has its own placebo? Yes. Separate placebo for each group. Great. So roughly, we're talking about
00:23:11 four groups. The E only is roughly 5,000 plus 5,000, where they randomized one-to-one. Exactly.
00:23:17 And then the E plus P would have been roughly 8,500 in E plus P and then 8,500 placebo for that
00:23:25 group. Correct. Okay. Primary outcome, was there a single primary outcome and was it ASCVD? Was that
00:23:31 the main outcome? The primary outcome for both trials was coronary heart disease with the primary
00:23:39 safety outcome because of concern, even before the study was designed, was breast cancer. So the two
00:23:48 really key outcomes of the trial were coronary heart disease and breast cancer.
00:23:54 And obviously, this is incidence of breast cancer, not mortality of breast cancer, correct?
00:23:58 Incidence. A diagnosis of breast cancer that's confirmed by medical record review.
00:24:03 And coronary artery disease would be what we would think of today as MACE. So major adverse
00:24:09 cardiac event, MI, stroke, death as a result of anything, or was it more complicated?
00:24:14 The primary outcome was actually the coronary events. So it was heart attacks. It was either
00:24:22 non-fatal heart attack or fatal coronary disease, which is most commonly a fatal heart attack.
00:24:30 What was the study powered to detect on either of these? Obviously, those numbers,
00:24:38 the study subjects is something that I'm sure the investigators thought long and hard about.
00:24:42 What was the power analysis suggesting a difference that was anticipated?
00:24:46 Remember that the prior hypothesis was that there would be benefit for heart disease and that there
00:24:54 would be overall many favorable effects of these hormones on chronic disease outcomes.
00:25:00 It was powered to detect an important clinical reduction such as a 20% reduction in heart disease.
00:25:11 Do you recall at the time what fraction of the women were taking lipid-lowering therapies?
00:25:18 How common would that have been in the early to mid-90s? You know, I think one of the interesting
00:25:24 aspects of the WHI is that, as you pointed out, hormones were being used as a preventive treatment
00:25:32 for ASCVD. You know, I think today very few physicians would really consider that. I think
00:25:38 given the complete explosion we've had in both the availability, variety, and efficacy of lipid-lowering
00:25:46 agents, a person who's deemed at risk is going to be managed much more critically with respect to
00:25:51 blood pressure and lipids. Again, I don't know that I've ever come across that stat. That may
00:25:56 not be something that you know, but I'm just curious as to how prevalent that was.
00:25:59 Yes, I do know it. It's right in the paper that we published in JAMA in 2013, and we published
00:26:06 repeatedly on the subject of the use of many of these medications for chronic health conditions.
00:26:12 So 7% of the study population was taking statins at the start of the study. By later in the trial,
00:26:24 during the intervention phase, it was over 25%. There was a very large increase in statin use,
00:26:33 even during the trial itself, and with longer follow-up. Obviously, these percentages are even
00:26:40 higher, getting to 40%, 50%, very high percentage. What was known about oral estrogen at the time?
00:26:48 Again, going back to the early to mid-90s, as far as its impact on coagulability, for example,
00:26:56 blood viscosity. Today, oral estrogen is not used very often as a result of that, but at the time,
00:27:02 what was known?
00:27:03 It was understood that oral medications and oral estrogen goes directly through the portal
00:27:12 circulation to the liver and has a direct effect on the liver in increasing the synthesis of clotting
00:27:20 proteins. That was understood at that time because similar to oral contraceptives, it had been seen
00:27:28 in observational studies that both oral contraceptives and postmenopausal hormone therapy are associated
00:27:35 with an increased risk of deep vein thrombosis and even pulmonary embolism. That had been suggested,
00:27:43 but it was believed to be relatively rare and that the benefits for heart disease and for other
00:27:51 chronic diseases would outweigh those risks of thrombosis.
00:27:56 What was your personal hypothesis going in? I mean, there's obviously the hypothesis that is
00:28:01 driving the study, but do you remember back, you know, gosh, it's probably 30 years now since you were
00:28:08 in the planning phase of this. What did you think was happening mechanistically to explain the observational
00:28:14 data? Did you believe the observational data? Did you think that they were being confounded heavily?
00:28:20 Do you have a recollection of that?
00:28:21 I believe that it was likely that there was at least a small amount of confounding because it was
00:28:29 clear that women taking hormone therapy tended to have a higher socioeconomic status, tended to have
00:28:35 better access to medical care and to have somewhat more favorable lifestyle behaviors, be more health
00:28:42 conscious. Many of these factors were considered in the data analyses. It's not like the observation
00:28:50 studies were just looking very crudely at associations. There was adjustment for many of these
00:28:56 lifestyle factors and socioeconomic status in some of the studies, but a benefit, a risk reduction for
00:29:05 heart disease did tend to persist even after those adjustments. My thought was that women in early 0.99
00:29:13 premenopause who are transitioning from having their natural premenopausal estrogen exposure,
00:29:22 which many studies suggested was protective, a cardioprotective favorable in terms of risk factor
00:29:31 status, in terms of dilating the blood vessels to the heart and increasing blood flow to the heart. There
00:29:38 were many studies already suggesting that a woman's own natural estrogen during premenopausal years was one of
00:29:45 the reasons why women started to have heart disease later, 10 years or more later than men. My thoughts were that
00:29:53 it is likely that starting estrogen in early menopause would translate into at least a slightly lower risk of heart
00:30:03 heart disease. But I was skeptical from the very start that the magnitude of risk reduction seen in the
00:30:11 observational studies, you know, the 40%, 50% lower risk of heart disease would stand up to a randomized clinical trial
00:30:23 assessment of this question. So I thought it was likely to be a small reduction, wasn't sure whether that benefit might be
00:30:32 offset by other risks that would be identified. But overall, you know, I thought there's likely to be some
00:30:40 confounding going on in the observational studies.
00:30:44 When you think back to, again, that same period of time, what was your thinking with respect to the relationship
00:30:49 between estrogen and breast cancer? You know, obviously the classical teaching, I mean, I was in medical school in the
00:30:54 mid-90s and you were taught chapter and verse that estrogen causes breast cancer. But on the surface, some of the
00:31:01 assumptions are a little hard to understand. In the same way that there has historically been the assumption
00:31:04 that testosterone causes prostate cancer, except for the observation that men with the highest levels
00:31:10 of testosterone, i.e. men when they're, you know, younger, have lower rates of prostate cancer than men
00:31:14 when they're older. And similarly, I mean, this was demonstrated as long as 15 years ago that the lowest levels
00:31:19 of testosterone were associated with the most aggressive forms of prostate cancer. I don't know how similar the
00:31:25 data are for estrogen and breast cancer, but given that most women get breast cancer in menopause and
00:31:32 not prior to menopause, they're getting breast cancer, even estrogen-sensitive breast cancer at a time when
00:31:37 they have their lowest levels of estrogen. So what was the understanding of the pathophysiology of the
00:31:42 relationship between estradiol or estriol even and, or maybe it's estrone, it was deemed to be even more
00:31:49 problematic. What was the understood relationship for why that relationship existed?
00:31:53 There was an expectation that there would be at least a modest increase in risk of breast cancer
00:32:01 with giving either estrogen plus progestin or estrogen alone. In fact, the most surprising
00:32:08 finding in terms of breast cancer was that no increased risk of breast cancer was seen with estrogen
00:32:15 alone, even though the observational studies had suggested that both estrogen plus progestin and
00:32:22 estrogen alone would be associated with increased risk of breast cancer. But there were many, many
00:32:29 observational studies suggesting that hormone therapies associated with increased risk of breast
00:32:36 cancer, but the thinking tended to be these are estrogen receptor positive breast cancers. They tend to be
00:32:44 more favorable outcome types of breast cancer. And that breast cancer mortality would not be appreciably
00:32:54 increased. So that was the thought going into it. And also in the observational studies, there was
00:33:01 always that concern that differences in mammographic screening patterns could be contributing to greater
00:33:09 detection of breast cancer among women taking hormone therapy because most doctors would not continue to
00:33:16 prescribe the hormone unless the woman was having regular mammography and showed a normal mammogram
00:33:23 without concern about a lesion there. So mammography also could have been contributing more frequent
00:33:30 mammography in women on hormones versus women not taking hormone therapy could have contributed somewhat to the
00:33:38 increased risk in the observational studies, which was why it was important to look at this question
00:33:43 in a randomized clinical trial with uniform surveillance for breast cancer with a mammogram being required every
00:33:53 year. So there was an increased risk of breast cancer with estrogen plus progestin. Also, there were denser
00:34:02 breasts developing over time. So breast density was looked at in a study of mammograms, several hundred
00:34:11 women whose mammograms were examined, and there was a change in increased breast density, which is known to be a risk 0.94
00:34:21 factor for breast cancer. The increase in breast density was greater with estrogen plus progestin than with estrogen
00:34:28 alone. Now, what was really surprising, as I mentioned, although there was this increase, 25-30% increase in risk of breast
00:34:38 cancer seen with estrogen plus progestin, there was no increase in breast cancer seen with estrogen alone. And with longer
00:34:47 follow-up, there was the emergence of a reduction in breast cancer close to a 20% reduction seen with the conjugated
00:34:56 estrogen. And the view was that this may be something specific to conjugated estrogen, which is a relatively
00:35:04 weak estrogen, and may have certain properties similar to tamoxifen, where it may be both serving as an estrogen
00:35:14 and an anti-estrogen. But we cannot assume, importantly, we cannot assume that this finding with conjugated
00:35:23 estrogen will necessarily apply to all formulations of estrogen alone and certainly will not apply to
00:35:33 the combination of estrogen plus progestin. So that's interesting, Joanne. I wouldn't come to that as my
00:35:40 first kind of Occam's razor conclusion because the same conjugated equine estrogen was used with the MPA
00:35:47 that found a clinically irrelevant but statistically significant increase in the incidence of breast
00:35:54 cancer. In other words, I wouldn't conclude from the differences in those two arms that it was the
00:36:01 conjugated equine estrogen that was unusually beneficial. No, I'm not. I'm not concluding.
00:36:07 Wouldn't it be that the MPA was the difference? Yes, it's the MPA. But the only way to look at
00:36:13 the role of the estrogen is in the estrogen alone trial because in the estrogen plus progestin trial,
00:36:21 you can't disentangle. It was given a combined pill. Every woman in the trial was taking the
00:36:26 combination. So I completely agree with you, Peter. The increased risk of breast cancer seen with estrogen
00:36:33 plus progestin was mostly attributable, if not entirely attributable, to the progestin,
00:36:42 to the medroxyprogesterone acetate. And of course, the question has been raised, would other types of
00:36:49 progestogens, such as the bioidentical micronized progesterone, would that also lead to an increased
00:36:57 risk of breast cancer? There are some observational studies that suggest less increase in breast cancer
00:37:03 with that particular formulation of progestogen. However, we have no large-scale randomized clinical
00:37:13 trials that have done head-to-head comparisons or even really tested long-term the effects of other
00:37:21 formulations of progestogen on breast cancer risk. So probably the most prudent and cautious approach is
00:37:29 to assume that at least with longer duration of treatment with estrogen plus progestin,
00:37:35 there will be an increased risk of breast cancer. Let's go back and talk about the study being
00:37:41 stopped. So the E plus P arm, so the CEE plus MPA arm was stopped early, correct? A little over five years?
00:37:48 It was stopped after 5.6 years, and it was stopped 3.3 years early.
00:37:55 And this was stopped presumably on the basis of the finding for the increased incidence of breast
00:38:01 cancer, correct? It was stopped on the basis of the increased risk of breast cancer together
00:38:08 with no reduction in heart disease, which was the primary endpoint, and an overall unfavorable
00:38:17 risk-benefit ratio as shown through the global index, which looked at all of these chronic conditions.
00:38:23 Now, one of the things that I didn't realize until somewhat recently was that the dropout rate
00:38:30 was a little bit unusual in that in the placebo arm of the E plus P group in the
00:38:36 first, second, third year relative to the final year. Do you recall what those numbers were?
00:38:41 The dropout rate is actually substantial in all hormone therapy trials. It's a combination
00:38:48 of people do dropout of all trials because it requires a lot of effort to take a medication
00:38:56 that's not being prescribed for your health. It's just part of a study. You don't know exactly
00:38:59 whether it's active or placebo. So all trials have some dropout over time in terms of compliance,
00:39:07 adherence with study medications. Also, there are some side effects of hormone therapy. The women who had an
00:39:14 an intact uterus and were taking estrogen plus progestin, some of them continued to have some
00:39:20 vaginal bleeding, and some of them did not want to continue to have those symptoms. They may have
00:39:25 had some breast tenderness or other symptoms and dropped out. And women dropped out of the placebo
00:39:32 arm as well. Some of that is just taking a medication day in and day out, taking a study pill. Fatigue will
00:39:39 set in in any randomized trial. Our participants were extraordinarily dedicated. I cannot imagine
00:39:47 any group being more committed to women's health and to getting answers for women on these very
00:39:53 pressing issues in menopausal women's health. But there's going to be some dropout in any trial. 1.00
00:40:00 Do you think the answer might have been different if the trial had gone to,
00:40:04 it was originally planned to be about nine years? Over eight years. I mean, I guess we'll never know
00:40:11 what it would have shown had it gone longer. So at the time that the study was halted,
00:40:16 really the big headline of the study was estrogen causes breast cancer. I use this as a great teaching
00:40:23 example when I talk about the difference between relative risk and absolute risk. The relative risk
00:40:28 difference in the group that was CEE plus MPA relative to placebo or versus placebo was 24, 25%,
00:40:36 correct? Yes. I think it was a little higher. On the surface, that sounds incredibly startling,
00:40:41 right? So women who are getting CEE plus MPA have a 25% higher risk of breast cancer during this 5.2 year 0.82
00:40:49 period. The absolute risk increase was 0.1%. It was a difference of one case per thousand.
00:40:55 Exactly. The women in the placebo group were getting breast cancer at an incidence of four 0.93
00:41:01 cases per thousand women. The women in the CEE plus MPA group were getting it at an incidence of
00:41:07 five cases per thousand. The absolute difference of that being one case per thousand. It was about
00:41:13 the opposite that was seen in the CEE versus placebo alone, although I don't think it reached
00:41:19 statistical significance at 5.2 years, did it? No, it didn't.
00:41:22 It took longer follow-up to see that reduction. Yes.
00:41:27 To see that there was indeed a reduction. In many ways, it seems that that was the headline
00:41:33 that dominated the world. I don't have any recollection of it at the time, Joanne, because
00:41:37 I was in my surgical residency when the study was first published, and I must admit, I wasn't paying
00:41:42 attention to this literature. I'm embarrassed to admit, I don't even recall this paper coming out.
00:41:46 What is your recollection of that time? How much it sort of captured the imagination and fear of the
00:41:51 world? Well, the medical community was shell-shocked. There was a sea change in clinical practice,
00:41:59 a seismic shift in clinical practice. But let's think about what the shift was. Two major things
00:42:07 changed. There was a dramatic reduction in use of hormone therapy, 70% to 80% reduction in use of
00:42:16 hormone therapy. So women who were being prescribed hormone therapy in the past for prevention of 0.98
00:42:24 chronic diseases, prevention of heart disease, stroke, cognitive decline, those women were no longer
00:42:31 being prescribed hormone therapy. And that was a positive thing. That was a positive change in
00:42:38 clinical practice because the WHI showed that when hormone therapy is used for prevention of
00:42:47 chronic disease purposes in women who have average age of 63 and women in mid to later menopause on
00:42:54 average, the risks outweighed the benefits. So it was a favorable change. But the unfavorable change in
00:43:00 clinical practice was that the results were extrapolated to women in their 40s and 50s who were taking
00:43:08 hormone therapy for treatment of bothersome, even distressing, hot flashes, night sweats, and were in
00:43:15 generally good health. And they were being denied hormone therapy to relieve these symptoms. And that was an
00:43:24 inappropriate extrapolation of the findings. That was a negative outcome. Women never should have been 1.00
00:43:34 denied hormone therapy for the treatment of bothersome, distressing, hot flashes, night sweats to improve
00:43:42 their quality of life, especially generally healthy women in early menopause who have such low absolute 1.00
00:43:48 rates of adverse events. Now, as you say, in the WHI, even in the overall cohort with an average age of 63,
00:43:58 most of the adverse events were relatively rare, such as one extra case of breast cancer or heart attack
00:44:09 or blood clot per 1,000 women per year. I mean, it's still important and it can add up with longer term use.
00:44:17 However, it's a low absolute risk. And I think that the results were perhaps blown out of proportion,
00:44:29 especially in terms of the use of hormone therapy for a clear indication, an FDA-approved indication of
00:44:36 treatment of hot flashes and night sweats among women in early menopause who had even lower absolute
00:44:42 risks than one extra case per 1,000 women per year. And that type of extrapolation really should not have
00:44:52 happened. So there were some positive outcomes that hormone therapy was being used less for inappropriate
00:45:02 purposes, such as prevention of heart disease, stroke, cognitive decline, but also this unfavorable
00:45:10 change that it was being used less commonly for treatment of bothersome hot flashes and night sweats
00:45:18 in early menopause.
00:45:20 I guess what I find most troubling is that when I speak with most physicians today, unless they're really,
00:45:26 really steeped in this world, and most aren't, they can't reiterate what you just said. The only thing
00:45:33 that they seem to understand, and by extension, the only thing that their patients seem to be led to
00:45:38 believe, you know, really the enduring legacy of the WHI from an insight perspective is that hormones,
00:45:47 in particular estrogen, cause breast cancer, and that HRT is synonymous with breast cancer.
00:45:54 And there are really two enormous inaccuracies in that that are so inaccurate that they're almost a
00:46:02 parody, right? And when we've discussed them both, but I think it's always worth bringing it back
00:46:06 for the listeners so that they aren't lost in the details. The first is that nothing about this
00:46:11 study suggested that estrogen is causing breast cancer. If anything, this study suggested MPA
00:46:18 is causing breast cancer based on the fact the group that was only receiving estrogen had a
00:46:24 reduction in the incidence of breast cancer, while the group that received estrogen plus MPA is the
00:46:29 group that saw this small, potentially statistically significant, but potentially clinically
00:46:34 insignificant increase. The second thing that seems to get lost from this, and again, it's sad that
00:46:40 most doctors and patients who are contemplating HRT don't recognize this, is that the study only found
00:46:45 an increase in the incidence of breast cancer to the tune of one case per thousand, but no difference
00:46:51 in mortality. One has to wonder what the cost of that was. Let's talk about some of the other outcomes
00:46:59 here. First of all, would you agree with that, by the way, that that would be perhaps a more
00:47:02 charitable interpretation of the WHI? Two caveats. One, I think we cannot assume what was found with
00:47:09 conjugated estrogen will apply to all other formulations of estrogen, and I think there is
00:47:15 very strong evidence from several lines of biology that estrogen plays a role in breast cancer, including
00:47:24 the fact that when women have their ovaries removed, it lowers their risk of recurrence, lowers the risk of
00:47:31 development of breast cancer, lowers the risk of recurrence, and I think there is quite a bit of
00:47:37 evidence that estrogen does play a role. The higher estrogen, estrone, would be specifically the type of
00:47:45 estrogen that, for example, is associated with increased adiposity, and postmenopausal women is linked to a higher
00:47:53 risk of breast cancer. So I think there are several lines of evidence that estrogen is a factor in breast
00:48:01 cancer. And this was actually also known, even before the WHI, that many of the observational studies
00:48:09 had linked hormone therapy to an increased risk of breast cancer. But I agree with you that it seems to be,
00:48:18 when you're talking about conjugated estrogen, it's the combination of estrogen plus the medroxyprogesterone
00:48:25 acetate. It may be specific to that particular progestin. We don't know. We have very limited
00:48:31 research in terms of randomized clinical trials, large-scale studies of other formulations of
00:48:38 progestin. In terms of breast cancer mortality, the results in the WHI are very close to a statistically
00:48:48 significant increase in breast cancer mortality with estrogen plus progestin. It doesn't quite make
00:48:56 statistical significance, but it is getting toward a significant increase in risk. On the other hand,
00:49:04 the conjugated estrogen alone was associated with a statistically significant reduction in breast
00:49:12 cancer mortality. So really diametrically opposite effects of the combination with the medroxyprogesterone
00:49:21 acetate of the estrogen with the medroxyprogesterone acetate versus the conjugated estrogen alone. I think
00:49:28 that the absolute risks are still low. And that is a very important point to emphasize that we are
00:49:36 talking about one extra case per thousand women per year. For a woman who starts out with a high 1.00
00:49:45 baseline risk because of a strong family history or other risk factors, this would certainly be something
00:49:50 she would want to avoid. But for a woman in early menopause at usual risk of breast cancer, 0.71
00:49:56 who would derive the benefits of symptom relief and she's suffering from disrupted sleep, very
00:50:03 bothersome hot flashes and night sweats that interfere with her day-to-day activities, this would be a risk 0.97
00:50:10 that she would probably be willing to accept with an understanding that all medications have some risks and
00:50:18 that she could be monitored closely with mammography and breast exams. And, you know, usually there would not be
00:50:26 a fatal form of cancer diagnosed. Overall, we did not see any significant increase in total cancer,
00:50:36 total invasive cancers with either estrogen plus progestin or estrogen alone. And interestingly,
00:50:42 with the combination estrogen plus progestin, we saw a significant reduction in the endometrial cancer,
00:50:51 the uterine cancer developing over time and colorectal cancer also seem to be at least borderline reduced.
00:51:01 So I think the clinical message and the message for the public is that hormone therapy has very complex
00:51:09 effects. It has a complex matrix of benefits and risks that vary according to a woman's age,
00:51:21 her time since menopause, her underlying health status, and decision-making about hormone therapy really has to be
00:51:30 individualized, personalized, and women themselves play such an important role in the shared decision-making. 0.98
00:51:40 Because many women will say, I do not want to take hormones no matter what, and even if a woman's at low risk,
00:51:46 and the doctor or clinician may think that they really should consider hormone therapy, that's the woman's decision, 1.00
00:51:54 and you respect it. However, other women, let's say, will say that they want to take hormone therapy, 1.00
00:52:03 even though they know that there may be X, Y, or Z increased risk, because their symptoms are so bothersome,
00:52:13 they're so distressing, they're being disrupted, their sleep is being disrupted,
00:52:17 they are not being able to have work productivity, their day-to-day activities are affected, their quality of life is
00:52:25 really impaired. And it is very important that women be able to help make that decision together with their clinician
00:52:35 that they share in that decision-making.
00:52:37 I don't disagree with any of that. I guess the only issue I would potentially highlight is that in the scenario
00:52:43 you described where the physician thinks that it's the right thing to do, the patient is experiencing
00:52:50 vasomotor symptoms, the patient already has osteopenia, and their bone mineral density is only going to
00:52:57 decline with time, and they're not at unusually high risk for breast cancer. That scenario where the patient
00:53:03 is in, you know, almost a fear mode of saying, oh my god, no way I want, you know, HRT, it's going to cause
00:53:08 breast cancer. I guess what I'm arguing is that's a very ill-informed decision. So yes, it's their
00:53:13 decision, and yes, they should be able to make whatever decision they want, but that doesn't mean
00:53:17 it's a good decision, and that doesn't mean it's a decision based on good data. Because in reality,
00:53:21 it's not based on data. That's my fear, is that this is no longer about the data, because I think the data,
00:53:27 what you and I are discussing today is the data. And the data really don't make a very strong case
00:53:32 for avoiding HRT outside of select circumstances, and yet I worry that the last 20 years of women 1.00
00:53:39 entering menopause have been put into two categories, right? Either there are women who really want HRT, 0.91
00:53:45 but they can't find physicians who will give it, or there may be a physician who understands the data
00:53:50 at the level you and I are discussing it, but the patients themselves have been so frightened off it
00:53:54 by misinterpretations of the data. I think the conversation has to take place. And, you know,
00:54:01 it is important for the clinicians to be informed themselves about benefits and risks and be able
00:54:08 to discuss the benefits and risks in a very knowledgeable way with the patient. But my view
00:54:15 is that if a patient feels strongly that she doesn't want to take hormone therapy, maybe, you know, her mother
00:54:20 develop breast cancer while she was on the hormones, whether or not it was directly due to the hormones.
00:54:27 So she is going to have a lot of fear and anxiety surrounding use of hormone therapy, and that will 0.98
00:54:33 affect her overall well-being. That's a factor in the benefit-risk equation. So I would generally say,
00:54:42 don't push someone by just showing that the absolute risks in terms of number of cases,
00:54:48 cause versus prevented, might be favorable for them because their emotional well-being is a very
00:54:55 important part of the equation. However, I do agree that we need to emphasize absolute risks,
00:55:02 that absolute risks are low, and that there are better candidates and there are worse candidates.
00:55:09 It's amazing how the pendulum has swung. So in the 1980s, 1990s, the perception was that hormone therapy
00:55:18 was good for all women. Women were being routinely started on hormone therapy. Then after the WHI in 1.00
00:55:24 the early 2000s, the pendulum was in the opposite direction, that hormone therapy is bad for all
00:55:32 women. And now I think it is coming, the pendulum is coming to rest in a more appropriate place,
00:55:37 that hormone therapy is good for some, but not all women. And the best candidates are women in early 1.00
00:55:44 menopause who have moderate to severe or bothersome hot flashes and night sweats and are in generally
00:55:51 good health. Those are women who will derive quality of life benefits and have very minimal 1.00
00:55:57 absolute risk from hormone therapy. One of the things I've thought a lot about is how many women, 1.00
00:56:03 if you go back to 2002 and the data are published, but the media has a different take on it. The media
00:56:11 has the take on it, which is kind of how we're discussing it now. Not very exciting. So maybe
00:56:17 that's why that's not the take the media had, but I play the what if game, which is how do things shake
00:56:22 out? So instead of the pendulum going so far to the other side of women can't and shouldn't under 1.00
00:56:29 any circumstance have HRT because they're going to get breast cancer, it turns into, no, there will be 1.00
00:56:34 additional cases of breast cancer. I've done sort of a back of the envelope calculation based on
00:56:38 the assumption that somewhere between four and five million women probably missed out on HRT in the
00:56:44 last 23 years, 22, 23 years as a result of the study, which saved, mean it reduced about 4,500
00:56:52 cases of breast cancer. There's benefit to that. Didn't really reduce mortality from breast cancer, 0.92
00:56:58 but here's what's interesting. Even though it's not a primary outcome, HRT reduced the incidence of hip
00:57:05 fracture by about one and a half percent in absolute terms. That's remarkable.
00:57:09 Yes, there was the benefit for hip fracture and there were benefits for-
00:57:15 In other cancers as well.
00:57:16 Yes, there were benefits for endometrial cancer with estrogen plus progestin. But here's the problem
00:57:22 with the whole argument for using it for bone health. Women in their forties and fifties have a low 1.00
00:57:29 risk of osteoporotic hip fracture. They may have a hip fracture from a traumatic incident, but it's not
00:57:37 likely to be related to osteoporosis. So it's when they get into their late 60s, 70s, 80s, that they're
00:57:44 more likely to have the osteoporotic fractures. And if we were to treat women from early menopause into
00:57:53 their 70s, 80s, that would be very long duration of hormone therapy use, which would lead, especially
00:57:59 combination hormone therapy, would lead to an increased risk of breast cancer. And once women 1.00
00:58:03 go off of hormone therapy, bone loss is very rapid. So all of the benefits to the bones in terms of
00:58:12 preserving bone mineral density, that dissipates very quickly within a matter of a few years after
00:58:20 stopping hormone therapy. So that if a woman is taking hormones in her forties and fifties,
00:58:27 and then she stops, let's say at age 60, then by the time she gets to the age where her risk of hip
00:58:34 fracture is very substantial in her seventies and eighties, she's really not going to have a persistent
00:58:40 sustained benefit from the hormone therapy. And we looked within the group at high risk of
00:58:47 osteoporotic fracture, whether they had a favorable, overall favorable outcome in terms of the global
00:58:54 index combination of all of these outcomes with hormone therapy. And overall, there really was no
00:59:00 group of women, irrespective of their risk of osteoporotic fracture, who had a clearly beneficial
00:59:09 ratio from benefit risk ratio from estrogen combined with progestin when used for chronic disease
00:59:17 prevention. Again, this does not mean that it isn't a very effective treatment for hot flashes and
00:59:24 night sweats, and that women in early menopause would have a favorable benefit risk profile taking
00:59:31 into account the quality of life benefits. We haven't talked about age differences. I think that
00:59:38 overall, it's so important for women to understand that the absolute risks of these hormones are much
00:59:46 lower in early menopause than in later menopause. And in many ways, timing is everything when it comes to
00:59:55 hormone therapy, because not only are the absolute risks, the risk of having adverse events on hormone
01:00:02 therapy lower in the younger women, women in early menopause, but also we saw some signals that especially
01:00:09 with estrogen alone, the women in their 50s, the youngest women in the study were 50 to 59, those women
01:00:18 tended to do quite well in terms of heart disease and heart attack rate compared to the women on 1.00
01:00:25 placebo. There was a signal there for benefit, also a signal there for favorable outcomes in terms of all
01:00:32 cause mortality. So overall, there were favorable signals with estrogen alone in the younger women,
01:00:39 and also lower risks of adverse events, suggesting that certainly for estrogen alone in a woman who's
01:00:48 had a hysterectomy, if she is symptomatic with hot flashes, night sweats, the benefits of treatment are
01:00:54 likely to outweigh the risk. And even for combination estrogen plus progestin, despite what may be a small
01:01:02 increase in risk of breast cancer, the benefits are likely to outweigh the risk, even combination
01:01:09 therapy when used for the purpose of treating bothersome, disturbing, hot flashes, night sweats, disrupted
01:01:17 sleep, and impaired quality of life. And women should not shy away from the use of hormone therapy and should 0.99
01:01:24 discuss the option, weigh the benefits and risks carefully with their healthcare provider, with
01:01:29 their clinician, and see if it's the right decision for them. And if they have trouble finding a
01:01:35 clinician, they can go to the North American Menopause Society has a website, menopause.org,
01:01:41 and they can find the tab for find a healthcare professional, a certified healthcare professional
01:01:48 with training in menopause. And they can put in their zip code and find the clinicians in
01:01:54 their area who have this expert training. I'm an endocrinologist, and I know that many
01:02:00 endocrinologists have the training to talk about hormone therapy and discuss hormone therapy with
01:02:07 patients. But many clinicians have had limited training in, you know, use of hormone therapy,
01:02:15 and it may be helpful for women to seek out a clinician who has had some additional training
01:02:23 in menopause management and hormone therapy pros and cons. And for women who are not good candidates,
01:02:30 the good news is that there are non-hormonal options as well. They're not quite as effective
01:02:37 as the menopausal hormone therapy for treating hot flashes and night sweats. But some of the antidepressant
01:02:45 medications, SSRIs, SNRIs, some of the gabapentin, pentanoid medications, these medications have been found
01:02:54 to be quite effective, 40-50% reduction in hot flashes and night sweats with these medications. And there's a new
01:03:04 medication that may be approved by the FDA fairly soon that works entirely in the brain in terms of making women 0.99
01:03:12 less sensitive to the changes in temperature and has a very beneficial effect in terms of preventing hot
01:03:21 flashes and night sweats.
01:03:23 I guess I still kind of come back to something that the math doesn't quite add up, right, which is
01:03:28 if a woman stays on estradiol for the duration of her life, say from age 50 to 80, we accept that there's 0.97
01:03:37 going to be an increase in the incidence of breast cancer, though it doesn't seem to translate to a
01:03:41 difference in lifespan. But on the flip side, we are reducing her risk of fracture during a very
01:03:48 dangerous window. So the incidence of fracture saved is about one and a half percent, and the mortality
01:03:54 of that once she reaches 65, the one-year mortality, depending on the series, is 15 to 30 percent. So even
01:04:01 if we just want to do this on the basis of mortality, apples to apples, it doesn't even appear close,
01:04:07 does it?
01:04:08 Well, let's look at the actual data, because we published in JAMA 2017 the mortality results,
01:04:16 the all-cause mortality results by age and time since menopause. And we did see that the younger
01:04:24 women, the women who were in their 50s taking either estrogen alone or estrogen plus progestin,
01:04:30 had signals for about 30 percent lower mortality, though it was not statistically significant in either
01:04:37 trial. Yet the women who were older in their 70s, 70 to 79 randomized to estrogen alone, had a hazard
01:04:49 rate 22 percent higher risk of all-cause mortality. It was not quite statistically significant. So it was
01:04:58 right at the border of being statistically significant. And with estrogen plus progestin,
01:05:05 it was actually quite neutral, almost completely null. So estrogen alone seemed to be just a tad worse
01:05:14 in the women, 70 to 79, though it was a tad better among the women, 50 to 59. So again, timing is
01:05:22 everything when it comes to the all-cause mortality results. There are favorable signals for the hormone
01:05:30 therapy. The women earlier in menopause, age 50 to 59 in the study, quite neutral results in age 60 to
01:05:39 69. But in age 70 to 79, there's a bit of a signal that estrogen alone may be linked to a small increase
01:05:49 in risk of mortality. That is a little different than what I was asking. I don't think the study can
01:05:54 answer the question I was asking, which is really more of conjecture that if a woman is started at
01:06:00 the appropriate time, which I think we all agree is during the transition from perimenopause to
01:06:05 menopause. And I'm really asking this question through the lens primarily of hip fracture, which I think
01:06:09 is just such an underappreciated cause of mortality in both men and women over the age of 65. But estrogen
01:06:16 is hands down the most important hormone as it pertains to signal transduction from the strain gauge
01:06:23 within the muscle to the osteoblast and osteoclasts. And so what I'm really asking is, it's more of a
01:06:29 thought experiment. If we put women on HRT at 50, and they stay on HRT for 30 years, by my calculation, 0.99
01:06:37 it's a 15x reduction in mortality. Because even if you accept a slightly higher incidence of breast
01:06:44 cancer, it's being more than dwarfed by the reduction in the hip fractures that they will be sustaining
01:06:50 15 years after beginning. Again, we don't know the answer, and we'll never know the answer, because I don't
01:06:55 think anyone's going to do that study. But the magnitude of that difference is so great. And that's where I just
01:07:00 think the discussion is very confusing for people, because they only see one thing, which is breast cancer. And
01:07:06 they don't see it through the nuanced lens that we're talking about it, which is why I'm glad we're talking
01:07:10 about it. I think this is the discussion people need to understand.
01:07:13 I agree that there may be an excessive focus on one isolated outcome, such as breast cancer,
01:07:21 when it's really the overall health of the woman. And of course, all-cause mortality is an integration 0.85
01:07:27 of all of these life-threatening health conditions. And it was quite neutral with hormone therapy.
01:07:34 Overall, the results were what we call null for all-cause mortality. There was no increase in risk
01:07:41 or decrease in risk in the overall study population. And in the younger women, there was a signal for some
01:07:48 reduction in risk. But a randomized trial has never been done that would look at 30 years of hormone
01:07:58 therapy treatment, starting in early menopause and continuing into mid to later menopause. And the
01:08:07 reality is we don't know whether the benefits would outweigh the risks. I know that some women will make 1.00
01:08:14 the choice to continue to take hormone therapy into middle to later menopause because they started in
01:08:23 early menopause. They did well on the hormones. Their quality of life is very good. When they try to stop or
01:08:30 reduce the dose, they feel hot flashes coming back and they end up taking these hormones well into
01:08:35 their 60s, 70s, even longer. And in the observational studies, this looks like it has a relatively
01:08:44 favorable benefit-risk ratio. However, keep in mind, this is a very select group of women who are
01:08:51 choosing to stay on hormone therapy long-term because they're doing extremely well with it and
01:08:58 they've tolerated it well and they haven't developed any of these interim events such as a heart attack,
01:09:03 a stroke, a blood clot in the legs or lungs, or breast cancer or other estrogen-sensitive cancers.
01:09:09 That's right. So we're selecting for healthier women. 1.00
01:09:12 It's a highly selective group of women. And I think that overall, we just don't know what a 1.00
01:09:18 randomized trial would show with long-term hormone therapy. But I think there would be concern that
01:09:23 the risk would outweigh the benefits because keep in mind, the WHI showed an increased risk of stroke
01:09:29 with both estrogen alone and estrogen plus progestin. And there was cognitive decline and
01:09:35 increased risk of cognitive decline among the women 65 and older, although that was not the case
01:09:40 in the younger women. But we just don't know how the pattern of benefits and risks would change
01:09:47 with longer duration once you get into 15, 20, 25 years of treatment.
01:09:54 Yeah. It's pretty clear to me we'll never get another bite at the apple as far as
01:09:59 going for that duration. But do you think we'll ever get another bite at the apple to use
01:10:04 kind of better practices? I mean, CEE and MPA have largely fallen out of favor. Very few women. 1.00
01:10:10 I've never actually seen a woman take those. I'm sure some do. But most women these days are using 1.00
01:10:14 the Vevel dot or one of the topical FDA patches, which is just pure estradiol. As you alluded to
01:10:21 earlier, most women these days are taking micronized progesterone, which is a bioidentical progesterone
01:10:25 or foregoing oral progesterone altogether and using a progesterone-coded IUD, which seems to offer
01:10:30 the same degree of local endometrial protection without any of the systemic effects for some women
01:10:36 who can't tolerate that. So in some ways, the entire cluster of insights from the WHI are less relevant
01:10:44 today, given that the drugs that were tested aren't the drugs that are in mass adoption.
01:10:48 Do you think it's likely we will see another short-term study, and I call short-term like kind of a five-year
01:10:55 study, that tests the same question using the current formulations and potentially does so in a manner
01:11:03 that is in line with more current use cases of the drug? Or do you think that that's too much of an undertaking
01:11:09 and something that we'll never really get another RCT to address?
01:11:13 I think that it is a good trend to move toward the transdermal, estradiol, and the micronized
01:11:22 progesterone, these FDA-approved bioidentical formulations of hormone therapy as opposed to the
01:11:31 oral conjugated estrogen, medroxyprogesterone acetate. I think that that is a good trend. We have to keep in
01:11:38 mind that we really don't know the long-term benefits and risks, but based on other, you know, in terms of
01:11:47 clinical outcomes, such as heart attacks, strokes, different forms of cancer, and all-cause mortality. But I think it
01:11:54 makes sense based on how these different formulations affect clotting, affect biomarkers for clotting, and
01:12:03 cardiometabolic health, blood pressure, all of those parameters. I think that there's reason to use the
01:12:11 transdermal and the micronized progesterone preferentially over the older formulations. I think
01:12:18 we need more randomized trials of these formulations that are now in more common use, especially looking at
01:12:26 breast density, mammographic breast density, to see if there is less suggestion of a future risk in
01:12:35 breast cancer based on the change in mammographic breast density, whether or not there is going to be
01:12:42 another large-scale trial of the magnitude of the Women's Health Initiative, which would be if you take
01:12:49 women in early menopause in order to have similar numbers of health outcomes and similar robust power 0.92
01:12:56 to look at health outcomes, it would have to be at least 40, 50,000 women being randomized in their
01:13:04 50s and followed for seven, eight years. I think it's really unclear whether such a trial could be
01:13:13 mounted, would be extremely expensive. And also, because of the rapid changes in formulations over time,
01:13:21 there would be the similar risk that the results might become obsolete by the time the results were
01:13:28 available, as you're suggesting is the case with the conjugated estrogen and MPA. But let's keep in mind
01:13:36 that even though the WHI was testing the most common formulations at that time in the early 1990s,
01:13:45 it did put an end to a practice of prescribing hormone therapy among women in later menopause for
01:13:55 the purpose of preventing strokes and heart attacks and cognitive decline, which actually were found in
01:14:02 the WHI to be adversely affected by hormone therapy. And women were not getting the benefits for quality of 0.99
01:14:11 life that many of them didn't have. Once they were in their late 60s, 70s, they were not having any hot
01:14:18 flashes, night sweats, disrupted sleep related to these symptoms. So they weren't getting the benefits
01:14:23 and they were getting these adverse outcomes. So it's important to acknowledge that the WHI did put an end to
01:14:32 what was an unfavorable practice. The problem was it was over extrapolated. The results were extrapolated
01:14:39 to women in early menopause taking hormone therapy for the hot flashes, night sweats. It's really
01:14:44 important for women to understand that the WHI results are really not intended to discourage a 1.00
01:14:53 woman who's having disrupted sleep, very severe, significant symptoms to discourage her from seeking help
01:15:01 and seeking hormone therapy as one of her options for treatment. And in her specific case in early
01:15:08 menopause and generally good health, the benefits are likely to outweigh the risk. That's the really
01:15:15 key message that women in early menopause should take these symptoms seriously, make sure they find a
01:15:22 clinician who will take these symptoms seriously and discuss their options, their treatment options,
01:15:30 review with them the pros and cons. And if they are not finding that clinician, they need to go outside
01:15:36 their current system and find a clinician who can help them to do that because there are many
01:15:43 clinicians out there who are knowledgeable in menopause management, knowledgeable in hormone therapy
01:15:48 decision-making, who can help them to make the best choice for themselves.
01:15:54 Joanne, what was the reference you gave for women to go and look for finding a provider near them
01:15:59 where they enter their zip code? What was the name of that again?
01:16:00 Menopause.org website of the North American Menopause Society. And they can go to the Find
01:16:08 a Certified Menopause Practitioner tab and it will give them an opportunity to put in their zip code
01:16:16 and then it will tell them which clinicians within five miles, 10 miles, have the expertise in menopause
01:16:25 management and hormone therapy and other treatments.
01:16:28 Well, I could continue talking with you for hours and extract so much more insight. There's so many other
01:16:33 topics. We could talk about vitamin D for another few hours.
01:16:36 That could be another. That could be another.
01:16:39 There's a whole other discussion. Yeah. I'll conclude with two things. I guess one is just I still remain
01:16:43 somewhat sad because I think there's a lost generation of women. I think there's 20 years of women who
01:16:48 entered menopause who were denied HRT due to the ignorance of their physicians and the irresponsibility
01:16:55 of the media. And I look at women like my mother and my mother-in-law who were entering menopause 0.99
01:16:59 just as the WHI was coming to its conclusion and who suffered unnecessarily. And I don't know how many
01:17:07 millions of women suffered unnecessarily. I think you're right. I think the pendulum is swinging
01:17:11 and I'd like to believe that there aren't women that are suffering that way today.
01:17:15 The other point I'd make is I really have always respected you and continue to do so because I feel
01:17:20 like you're one of the few people who was such an important part of the WHI who has been able to
01:17:26 look back at that and acknowledge its limitations. And I think your thinking seems to at least me
01:17:31 through your writing to have evolved over time. I don't think that's a property that is necessarily
01:17:36 inherent to everyone at your position. So I really applaud you for that. And I think that you're doing
01:17:41 more good today by speaking out on the limitations of the WHI than you probably even did by taking part
01:17:47 of the WHI. So thank you for that. And thank you for joining me today.
01:17:51 Well, thank you, Peter. I've enjoyed talking with you and I hope that these messages are helpful
01:17:56 to your audience. Thank you for listening to this week's episode of The Drive. If you're interested in
01:18:02 diving deeper into any topics we discuss, we've created a membership program that allows us to
01:18:07 bring you more in-depth exclusive content without relying on paid ads. It's our goal to ensure members
01:18:13 get back much more than the price of the subscription. To that end, membership benefits
01:18:17 include a bunch of things. One, totally kick-ass comprehensive podcast show notes that detail
01:18:23 every topic, paper, person, thing we discuss on each episode. The word on the street is nobody's
01:18:28 show notes rival these. Monthly AMA episodes or Ask Me Anything episodes, hearing these episodes
01:18:34 completely. Access to our private podcast feed that allows you to hear everything without having to
01:18:40 listen to spiels like this. The Qualies, which are a super short podcast that we release every
01:18:45 Tuesday through Friday, highlighting the best questions, topics, and tactics discussed on
01:18:50 previous episodes of The Drive. This is a great way to catch up on previous episodes without having to
01:18:55 go back and necessarily listen to everyone. Steep discounts on products that I believe in, but for
01:19:01 which I'm not getting paid to endorse. And a whole bunch of other benefits that we continue to trickle in
01:19:06 as time goes on. If you want to learn more and access these member-only benefits, you can head
01:19:10 over to peteratiamd.com forward slash subscribe. You can find me on Twitter, Instagram, and Facebook,
01:19:17 all with the ID peteratiamd. You can also leave us a review on Apple Podcasts or whatever podcast
01:19:24 player you listen on. This podcast is for general informational purposes only and does not constitute
01:19:30 the practice of medicine, nursing, or other professional healthcare services, including the giving of
01:19:35 medical advice. No doctor-patient relationship is formed. The use of this information and the
01:19:41 materials linked to this podcast is at the user's own risk. The content on this podcast is not intended
01:19:47 to be a substitute for professional medical advice, diagnosis, or treatment. Users should not disregard
01:19:53 or delay in obtaining medical advice from any medical condition they have, and they should seek the
01:20:00 assistance of their healthcare professionals for any such conditions. Finally, I take conflict
01:20:05 of interest very seriously. For all of my disclosures and the companies I invest in or advise,
01:20:11 please visit peteratiamd.com forward slash about where I keep an up-to-date and active list of such companies.
01:20:35 Thank you.